Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Coeptis Therapeutics Holdings (COEPW) Other Non-Current Assets (2021 - 2025)

Coeptis Therapeutics Holdings has reported Other Non-Current Assets over the past 5 years, most recently at $8.8 million for Q4 2025.

  • Quarterly results put Other Non-Current Assets at $8.8 million for Q4 2025, up 12.07% from a year ago — trailing twelve months through Dec 2025 was $8.8 million (up 12.07% YoY), and the annual figure for FY2025 was $8.8 million, up 12.07%.
  • Other Non-Current Assets for Q4 2025 was $8.8 million at Coeptis Therapeutics Holdings, up from $8.2 million in the prior quarter.
  • Over the last five years, Other Non-Current Assets for COEPW hit a ceiling of $8.8 million in Q4 2025 and a floor of $15833.0 in Q3 2024.
  • Median Other Non-Current Assets over the past 5 years was $3.5 million (2023), compared with a mean of $4.4 million.
  • Biggest five-year swings in Other Non-Current Assets: plummeted 99.48% in 2024 and later soared 51569.04% in 2025.
  • Coeptis Therapeutics Holdings' Other Non-Current Assets stood at $4.6 million in 2021, then plummeted by 92.38% to $348333.0 in 2022, then soared by 706.72% to $2.8 million in 2023, then surged by 179.24% to $7.8 million in 2024, then increased by 12.07% to $8.8 million in 2025.
  • The last three reported values for Other Non-Current Assets were $8.8 million (Q4 2025), $8.2 million (Q3 2025), and $8.5 million (Q2 2025) per Business Quant data.